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An exploration of testosterone levels in patients
with bipolar disorder
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Background
Testosterone influences well-being, mood and cognition and
may play a role in the pathophysiology of bipolar disorder.
Aim
To examine testosterone levels in patients with bipolar disorder
compared with healthy controls.
Method
We examined baseline total testosterone levels and current
depression scores in male and female patients with bipolar
disorder and mild to moderate depression and healthy controls.
Results
A significant interaction between diagnosis and gender was
observed (F(2,97)=9.791, P=0.002). Testosterone levels were
significantly lower for male patients with bipolar disorder
compared with male controls (P=0.001). Women with bipolar
disorder had significantly higher testosterone levels than female
controls (P=0.03).
Conclusions
Disturbances in testosterone levels may represent an
important neurobiological abnormality in bipolar disorder and
may differ by gender. If these findings are confirmed, the use of
gender appropriate treatment strategies for the normalisation
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Bipolar disorder is burdensome for the individual and for society;
it is associated with significant functional impairment, high
comorbidity, lower quality of life and higher rates of suicide.1
Pharmacotherapy with mood stabilisers and antipsychotics may
not lead to sustained remission and more than two-thirds of those
treated experience a recurrence within 5 years.2 Given such poor
treatment outcomes, novel approaches to improve therapeutic
interventions are an important objective of bipolar disorder
research. Mounting, albeit inconsistent, evidence suggests that
testosterone may play a role in the pathophysiology of mood
disorders.3 However, the effects of testosterone are complex: the
hormonal disorder polycystic ovarian syndrome is characterised
by chronically increased testosterone levels and is associated with
significantly increased depression,4 but paradoxically, ameliora-
tion of depression has been found following testosterone admin-
istration in males5 and females;6–8 low testosterone levels have
been reported in certain subgroups of men with depression;9
androgen-induced hypomania has been reported;10 and high
testosterone levels may predict suicidal behaviour in women
with bipolar disorder.3 Further evidence clarifying the relationship
between testosterone and bipolar disorder might pave the way for
exploring the use of pharmacological strategies that optimise
testosterone levels in patients with bipolar disorder. We therefore
assessed testosterone levels in bipolar disorder and healthy
controls and sought to explore whether this was different between
males and females and whether there was a relationship between
testosterone, mood and cognition.
Method
Participants and study setting
Participants in this study were 49 patients (male: n=30; female:
n=19) with a diagnosis of bipolar disorder (n=27 bipolar disorder I;
n=22 bipolar disorder II) and a current depressive episode
(confirmed with the Structured Clinical Interview for DSM-IV11),
who were 37 years old, and 37 education-matched healthy controls
(male: n=23; female: n=14). Here we report baseline data collected
as part of a study examining the effects of a glucocorticoid
receptor antagonist in bipolar disorder depression.12 Patient
medication was unchanged for 4 weeks before participation. After
a complete description of the study, written informed consent
was obtained from all participants. The study was carried out at
Newcastle University in the north east of England and was
approved by Newcastle and North Tyneside Local Research Ethics
Committee.
Neuroendocrine assessment
Blood samples were taken at 15.00 h. The blood was spun at
3000 rpm for 10 min in a refrigerated centrifuge, then separated
and stored at −80°C until assayed for total testosterone.
Testosterone was measured using the Roche Testosterone II assay
on the Roche Modular Analytics E 170 analyser. Internal quality
control involved material being assayed twice a day. The Clinical
Biochemistry team at Newcastle Hospitals participates in the UK
National External Quality Assessment Scheme (NEQAS) Steroid
External Quality Assessment (EQA) Scheme.
Mood symptoms
The following mood measures were administered: the Hamilton
Rating Scale for Depression (HRSD),13 the Montgomery and
Åsberg Depression Rating Scale (MADRS)14 and the Beck
Depression Inventory (BDI).15
Statistical analyses
Data were analysed using SPSS software (version 22 for Win-
dows). Baseline demographic, neuroendocrine and mood data
were compared between patients with bipolar disorder and
controls. Due to the normal distribution of the data, quantitative
characteristics are reported using means and standard deviations.
We report summaries for the characteristics and the results of
comparisons using independent-samples t-tests. Differences
between gender (male v. female) and diagnosis (control v. patient)
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in terms of testosterone levels were examined using as two-way
analysis of variance (ANOVA). All cited P-values are two-tailed,
with a significance level set at P=0.05.
Results
Demographic and clinical features of male and female patients
with bipolar disorder compared with healthy male and female
controls are outlined in Table 1.
A two-way ANOVA revealed a statistically significant inter-
action between gender and diagnosis on baseline testosterone
level, F(2,97)=9.791, P=0.002. These results together with the
independent-samples t-test indicated that male participants with
bipolar disorder had reduced testosterone levels compared with
male controls, t(51)=3.777, P=0.001, whereas female participants
with bipolar disorder had higher testosterone levels compared
with female controls, t(31)=–2.252, P=0.03.
No significant correlations were observed between total
testosterone levels and depression severity on the HRSD, MADRS
or the BDI in patients. We found no relationship between
testosterone and neuropsychological performance.
Discussion
To our knowledge, this is one of the first studies to directly
investigate differences in testosterone levels in participants with
current depression with bipolar disorder compared with healthy
matched controls. Testosterone levels were found to be signifi-
cantly lower in male patients with bipolar disorder depression
compared with male controls, whereas female participants with
bipolar disorder depression had significantly higher testosterone
levels than female controls.
These findings support earlier work showing low testosterone
in males with depression.8 In a recent study examining whether
testosterone predicted suicide attempts in females with bipolar
disorder followed up prospectively for up to 2.5 years,3 the authors
reported that higher baseline testosterone levels predicted suicide
attempts during the follow-up period. Although the present study
was not a follow-up study and we did not investigate links with
suicide, we do report a consistent finding of abnormal testosterone
levels being significant also for females with bipolar disorder with
current depression.
To explore this finding further with a view to establishing new
treatments for bipolar disorder, further research is necessary to
confirm the role of testosterone in bipolar disorder and to
understand why this divergence in testosterone levels occurs in
males and in females with the illness. Important clinical questions
to explore in this field of research from both a biological and
psychological perspective are: (a) whether reduced anabolic or
androgenic effects caused by low levels of testosterone reduce
feelings of masculinity and therefore self-satisfaction and self-worth
in males; (b) whether an increase in the anabolic or androgenic
effects of testosterone reduce feelings of femininity, lowering self-
satisfaction and self-worth in females; (c) whether testosterone
could be a useful biomarker for bipolar disorder; (d) whether
testosterone could be a useful biomarker for depression per se; and
(e) whether testosterone levels are stable in the course of bipolar
disorder depression or could they reflect a worsening of bipolar
disorder symptoms, including signifying risk of suicide in females
with bipolar disorder.3 Additionally, a systematic review of the
effects of testosterone treatments would be important before
testosterone normalisation treatments are recommended.
Strengths and limitations
The study was relatively small and exploratory. We enrolled only
participants with bipolar disorder with current depression into the
study, therefore our findings may only relate to participants in this
particular phase of the illness. The strength of the study was that
the sample was clinically well characterised.
Implications
Pharmacological interventions for bipolar disorder depression can
be effective, yet many patients fail to respond to treatment. The
findings presented herein build on an existing literature that draws
attention to the role of testosterone in bipolar disorder and has
significant implications for clinical interventions. Expanding
treatment methods by incorporating hormonal monitoring may
reflect an important shift in addressing the treatment of bipolar
disorder using a more holistic approach. These preliminary
findings should be examined further to establish the consequences
of altered sex hormone levels in bipolar disorder depression.
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Table 1 Demographic and clinical features of patients with bipolar disorder compared with healthy controls
Male patients (n=30) Male controls (n=23) Female patients (n=19) Female controls (n=14)
Demographic and clinical featuresa Mean (s.d.)
Age, years 47 (10.0) 42 (15.4) 47 (9.1) 48 (10.7)
HDRS 18 (4.6) 0.1 (0.3) 21 (4.6) 0.1 (0.4)
MADRS 26 (8.7) 0.5 (0.9) 28 (8.5) 0.4 (0.7)
BDI 27 (10.5) 0.9 (1.5) 30 (11.3) 0.9 (1.2)
Testosterone level, nmol/L 11.3 (3.8) 15.5 (4.2) 1.4 (0.4) 1.2 (0.2)
BDI, Beck Depression Inventory; HDRS, Hamilton Rating Scale for Depression; MADRS, Montgomery and Åsberg Depression Rating Scale.
a. Missing mood measure data on n=2 male patients and n=3 female patients; n=2–7 male controls and n=3–7 female controls.
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